Branded Drug pricing Increased 158% Over Past 7 Years Compared To CPI Of 12%: Morgan StanleyMani
Hillary Clinton’s proposal to constitute a drug price task force following Mylan’s EpiPen pricing will focus on non-innovator BioPharma, according to Morgan Stanley. David Risinger and team point out in their September 7 research piece titled “Epipen controversy drives renewed drug price scrutiny” that R&D productivity has stepped dramatically higher in recent years with new molecular and new biological entity approvals hitting a 19-year high of 45 last year.
Epipen . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.